Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 16/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16044951 | 0.89 | CYP19A1 (0.45) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL16044327 | 0.84 | CYP19A1 (0.43) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL16043806 | 0.82 | FGFR1 (0.37) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL16046906 | 0.82 | CYP19A1 (0.39) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL16046031 | 0.82 | CYP19A1 (0.37) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL16043938 | 0.81 | CYP19A1 (0.42) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL16044861 | 0.81 | CYP19A1 (0.46) | CYP19A1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL16044034 | 0.81 | PIK3CA (0.41) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL16047266 | 0.81 | CYP19A1 (0.46) | PIK3CACYP19A1ALDH1A1 | |
| SCHEMBL29501246 | 0.80 | CYP19A1 (0.48) | PIK3CAPIK3CDPIK3CBMTORPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345902-B1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2019-10-30 | — | — | EP | claimed |
| EP-3345902-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | Dart NeuroScience (Cayman) Ltd (KY) | 2018-07-11 | — | — | EP | claimed |
| EP-2970212-B1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-04-25 | — | — | EP | claimed |
| EP-2970212-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | Dart Neuroscience (Cayman) Ltd (KY) | 2016-01-20 | — | — | EP | claimed |
| US-20160009691-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE, LLC | 2016-01-14 | — | — | US | claimed |
| US-9120770-B2 | Substituted pyridine and pyrazine compounds as PDE4 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-09-01 | — | — | US | claimed |
| US-20140315913-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC | 2014-10-23 | — | — | US | claimed |
| WO-2014158998-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2014-10-02 | — | — | WO | claimed |
| US-20250122172-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC | 2025-04-17 | — | — | US | disclosed |
| US-20230075774-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-03-09 | — | — | US | disclosed |
| US-11279691-B2 | Substituted pyridine and pyrazine compounds as PDE4 inhibitors | DART NEUROSCIENCE LLC (US) | 2022-03-22 | — | — | US | disclosed |
| CN-108299400-B | Substituted pyridine and substituted pyrazine compounds as PDE4 inhibitors | 达特神经科学(开曼)有限公司 | 2021-02-19 | — | — | CN | disclosed |
| EP-3345902-B1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2019-10-30 | — | — | EP | disclosed |
| EP-3345902-B1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2019-10-30 | — | — | EP | disclosed |
| US-20140315913-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC | 2014-10-23 | — | — | US | disclosed |
| US-20140315913-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC | 2014-10-23 | — | — | US | disclosed |
| WO-2014158998-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275531-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC | 2014-09-18 | — | — | US | disclosed |
| US-20140275531-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC | 2014-09-18 | — | — | US | disclosed |
| US-20140275531-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122172-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | PIK3CA 222/4885PIK3CD 229/4885PIK3CB 257/4885 |
| US-20140315913-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | PIK3CA 247/4885PIK3CD 281/4885PIK3CB 344/4885 |
| US-20140275531-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | PIK3CA 247/4885PIK3CD 281/4885PIK3CB 344/4885 |
| US-20160009691-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | PIK3CA 215/4885PIK3CD 226/4885PIK3CB 255/4885 |
| US-20230075774-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | PIK3CA 222/4885PIK3CD 229/4885PIK3CB 257/4885 |
| US-11279691-B2 | Substituted pyridine and pyrazine compounds as PDE4 inhibitors | PDE4A, PDE4B, PDE4D | PIK3CA 215/4885PIK3CD 226/4885PIK3CB 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.